Monday, April 30, 2012
Savara Pharmaceuticals, of Austin, Texas, reported top-line data from its Phase Ia study of AeroVanc, an inhaled antibiotic. AeroVanc (vancomycin hydrochloride inhalation powder) is a dry powder form of vancomycin in a capsule-based inhaler to treat respiratory methicillin-resistant Staphylococcus aureus infections in patients with cystic fibrosis (CF).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.